Seminars in Oncology Nursing
Volume 22, Issue 3 , Pages 152-162 , August 2006

EGFR-Targeted Therapy and Related Skin Toxicity

  • Linda Morse

      Affiliations

    • Corresponding Author InformationAddress correspondence to Linda Morse, RN, MSN, Dana-Farber Cancer Institute, 44 Binney St, LG1B12, Boston, MA 02115
    • ,
  • Pamela Calarese

References 

  1. Mass RD . The HER receptor family (A rich target for therapeutic development) . Int J Radiat Oncol Biol Phys . 2004;58:932–940
  2. Viale PH. Current Topics in Colorectal Cancer Targeting EGFR for Oncology Nurses. 2005, Project ID: 2752 ES 16, No. 2.
  3. Carpenter C , Cantley LC . Molecular targets in oncology . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Principles and Practice of Oncology . Ed 7. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004;p. 73–83
  4. Aberle MF , McLeskey SW . Biology of lung cancer with implications for new therapies . Oncol Nurs Forum . 2003;30:273–280
  5. Perez-Soler R . HER1/EGFR targeting (Refining the strategy) . The Oncologist . 2004;9:58–67
  6. Houlihan N , Tyson L , Wood L . Targeted Therapies in Non-Small Cell Lung Cancer. A Continuing Education Monograph for Oncology Nurses . Pittsburgh, PA: Oncology Education Services; 2005;
  7. Wood LS . Rationale for EGFR as a target for cancer therapy . Semin Oncol Nurs . 2002;18(suppl 4):3–10
  8. Stetler-Stevenson WC . Invasion and metastasis . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Principles and Practice of Oncology . Ed 7. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004;p. 73–83
  9. Vlahovic G , Crawford J . Activation of tyrosine kinases in cancer . The Oncologist . 2003;8:531–538
  10. Lockhart C , Berlin JD . The epidermal growth factor receptor as a target for colorectal cancer therapy . Semin Oncol . 2005;32:52–60
  11. Herbst RS . Review of epidermal growth factor receptor biology . Int J Radiat Oncol Biol Phys . 2004;59:21–26
  12. Huang S , Armstong E , Benavente S , et al.  Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR) (Combining anti-EGFR antibody with tyrosine kinase inhibitor) . Cancer Res . 2004;64:5355–5362
  13. Noonberg SB , Benz CC . Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily (Role as anticancer agents) . Drugs . 2000;59:753–767
  14. Halpern AC, Thomas M. Anti-EGFR therapy-related rash and other adverse events: Etiologies, prevention, and management. Teleconference, American Academy of CME, Inc, 2005. http://www.academycme.org/ Available at: (accessed May 11, 2006)
  15. Herbst RS , Shin DM . Monoclonal antibodies to target epidermal growth factor receptor positive tumors . Cancer . 2002;94:1593–1611
  16. Thomas M . Cetuximab (Adverse event profile and recommendations for toxicity) . Clin J Oncol Nurs . 2005;9:332–338
  17. Paez JG , Janne PA , Lee JC , et al.  EGFR mutations in lung cancer (Correlation with clinical response to gefitinib therapy) . Science . 2004;304:1497–1500
  18. Perez-Soler R , Delord JP , Halpern A , et al.  HER1/EGFR inhibitor-associated rash (Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum) . The Oncologist . 2005;10:345–356
  19. Perez-Soler R , Saltz L . Cutaneous adverse effects with HER1/EGFR-targeted agents (Is there a silver lining?) . J Clin Oncol . 2005;22:5235–5246
  20. Shepherd FA , Pereira JR , Ciuleanu T , et al.  Erlotinib in previously treated non-small cell lung cancer . N Engl J Med . 2005;353:123–132
  21. Busam KJ , Capodieci P , Motzer R , et al.  Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 . Br J Dermatol . 2001;1441:1169–1176
  22. Hidalgo M , Siu LL , Nemunaitis J , et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies . J Clin Oncol . 2001;19:3267–3279
  23. Janne PA , Gurubhagavatula S , Yeap BY , et al.  Outcomes of patients with advanced non–small cell lung cancer treated with gefitinib (ZD 1839; Iressa) on an expanded access study . Lung Cancer . 2004;44:221–230
  24. Clark C , Perez-Soler R , Siu L , et al.  Rash severity is predictive of increased survival with erlotinib HCL [abstract] . Proc Am Soc Clin Oncol . 2003;22:196; [abstract]
  25. Park J , Park BB , Kim JY , et al.  Gefitinib (ZD 1839) monotherapy as a salvage regimen for previously treated advanced non–small cell lung cancer . Clin Cancer Res . 2004;(10):4383–4388
  26. Saltz LB , Meropol NJ , Loehrer PJ , et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor . J Clin Oncol . 2004;22:1201–1208
  27. Saltz L , Rubin MS , Hochster H , et al.  Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGRF) [abstract 559] . Clin Cancer Res . 2001;7:3766; [abstract 559]
  28. Saltz L , Kies M , Abbruzzese JL , et al.  The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies . Proc Am Soc Clin Oncol . 2003;22: [abstract 204]
  29. Skarin A . Systemic and mucocutaneous reactions to chemotherapy. In: Atlas of Diagnostic Oncology . Ed 3. Philadelphia, PA: Mosby; 2003;p. 597–610
  30. Bejak A , Shepherd F , Tu D , et al.  Symptom response in non–small cell lung cancer (NSCLC) patients treated with erlotinib: Quality of life analysis of NSCLC. CTG BR-21 Trial . J Clin Oncol . 2005;23:625s; [abstract 7018]
  31. Kim E . Cutaneous adverse events associated with Tarceva . South San Francisco, CA: Genentech Medical Communications; 2005;
  32. King LE , Gates RE , Stoscheck CM , et al.  The EGF/TGF alpha receptor in skin . J Invest Dermatol . 1990;94(suppl 6):164S–170S
  33. Jost M , Kari C , Rodeck U . The EGF receptor—An essential regulator of multiple epidermal functions . Eur J Dermatol . 2000;10:505–510
  34. Hansen LA , Alexander N , Hogan ME , et al.  Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development . Am J Pathol . 1997;150:1959–1975
  35. Malik SN , Siu LL , Rowinsky EK , et al.  Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients . Clin Cancer Res . 2003;9:2478–2486
  36. Tan AR , Yang X , Hewitt SM , et al.  Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor . J Clin Oncol . 2004;22:3080–3090
  37. Baselga J , Rischin D , Ranson M , et al.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types . J Clin Oncol . 2002;20:4292–4302
  38. Shah NT , Kris MG , Pao W , et al.  Practical management of patients with non–small-cell lung cancer treated with gefitinib . J Clin Oncol . 2005;23:165–174
  39. McLaughlin P , et al.  The significance of hair changes associated with cetuximab . Oncol Nurs Forum . 2005;32:467–468 [Abstract 163]
  40. Busana KJ , Capodieci P , Motzer T , et al.  Cutaneous side effects in cancer patients treated with the anti-epidermal growth factor receptor antibody, C225 . Br J Dermatol . 2001;144:1169–1176
  41. Purdom M . Management of acneiform rashes related to gefitinib therapy . Clin J Oncol Nurs . 2004;8:309–310
  42. Pizzo B . New directions in oncology nursing care (Focus on gefitinib in patients with lung cancer) . Clin J Oncol Nurs . 2004;8:385–392
  43. Yamamoto DS , Viale PH , Zhao G . Picture this (Severe acneiform rash) . Clin J Oncol Nurs . 2004;8:631–641

PII: S0749-2081(06)00059-3

doi: 10.1016/j.soncn.2006.04.005

Seminars in Oncology Nursing
Volume 22, Issue 3 , Pages 152-162 , August 2006

Article Tools

* Image Usage & Resolution